UNSPSC 51162732: Oxymetazoline

This classification denotes an alpha-adrenergic agonist with the molecular formula C16H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 8VLN5B44ZY, chemically known as 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol but more generally known as oxymetazoline, which bears US NIH Compound Identifier 4636. European Medicines Agency schedules Oxymetazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09567MIG.

UNSPSC 51162732 Oxymetazoline, a Commodity code, covers pharmaceutical products including nasal decongestants and related OTC medications that state and local governments procure for community health programs, public health initiatives, and multi-jurisdictional cooperative pharmaceutical distribution networks. Recent solicitations show state and local buyers acquiring these products both as standalone procurements supporting specific health interventions and as part of broader multi-source generic pharmaceutical and OTC product contracts serving multiple agencies across regions. The issuing bodies include county health departments and state-administered cooperative purchasing alliances coordinating procurement for multiple member jurisdictions, indicating a mix of direct county-level procurement and regional aggregated purchasing vehicles.

Recent activity spans Florida and Minnesota-led multi-state cooperative purchasing. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, under a two-year contract with one-year renewal option, potentially funded through FEMA. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awarded vendor pricing effective July 1, 2026. Vendors in cooperative contracts must comply with cGMP and Drug Supply Chain Security Act requirements, maintain relationships with authorized wholesalers, and accept administrative fees; competitive evaluation emphasizes price competitiveness at 75 percent weight.